• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用特立帕肽多脉冲皮下输注成功治疗维生素D无反应性甲状旁腺功能减退症。

Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.

作者信息

Puig-Domingo Manel, Díaz Gonzalo, Nicolau Joanna, Fernández Cristián, Rueda Sergio, Halperin Irene

机构信息

Servei de Endocrinologia, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.

出版信息

Eur J Endocrinol. 2008 Nov;159(5):653-7. doi: 10.1530/EJE-08-0269. Epub 2008 Aug 14.

DOI:10.1530/EJE-08-0269
PMID:18703565
Abstract

OBJECTIVE

Hypoparathyroidism is usually controlled with calcium and vitamin-D supplements; in very few cases this treatment fails and teriparatide may be an alternative. We report the first case of hypoparathyroidism refractory to vitamin-D therapy requiring multipulse teriparatide treatment.

CASE REPORT

A 53 year-old woman presented severe hypocalcemia and hypomagnesemia after thyroidectomy. Preoperatively, mild hypercalciuria was detected with parathyroid hormone (PTH) 69 pg/ml (normal 10-45) and 25-OH-vitamin D 9 ng/ml (normal 20-40) and normal levels of magnesium. No response was seen with oral and i.v. calcium and magnesium, or even with 5 microg calcitriol/day, suggesting a vitamin-D resistance status. Calcium sensor and vitamin-D receptor gene mutation studies were negative.

INTERVENTIONS AND RESULTS

The following treatments were tried: i) s.c. recombinant human PTH (rhPTH) 1-34 plus oral calcitriol, calcium, and magnesium, was partially effective, but symptoms resumed 4 h after the injection of 20 microg rhPTH; stable calcemia was not achieved even with 4-6 injections/day of teriparatide; ii) two trials of heterologous parathyroid transplant were performed but rejection was detected 3 months after; iii) i.v. magnesium decreased rhPTH requirements but i.m. administration was not tolerated and iv) multipulse s.c. infusion of teriparatide achieved complete normalization of serum calcium, phosphate, magnesium, calciuria and magnesuria with relatively low rhPTH doses (25-35 microg/day) for more than a year.

CONCLUSIONS

Vitamin-D unresponsiveness leads to uncontrolled hypocalcemia when postsurgical hypoparathyroidism occurs; in situations of no response to usual or higher doses of vitamin-D and s.c. injections of rhPTH, treatment with teriparatide multipulse s.c. infusor is an effective and safe alternative.

摘要

目的

甲状旁腺功能减退症通常通过补充钙和维生素 D 来控制;在极少数情况下,这种治疗会失败,而特立帕肽可能是一种替代方案。我们报告了第一例对维生素 D 治疗难治的甲状旁腺功能减退症病例,该病例需要多次注射特立帕肽治疗。

病例报告

一名 53 岁女性在甲状腺切除术后出现严重低钙血症和低镁血症。术前,检测到轻度高钙尿症,甲状旁腺激素(PTH)为 69 pg/ml(正常范围 10 - 45),25 - 羟基维生素 D 为 9 ng/ml(正常范围 20 - 40),镁水平正常。口服和静脉注射钙和镁,甚至每日 5 微克骨化三醇治疗均无反应,提示存在维生素 D 抵抗状态。钙敏感受体和维生素 D 受体基因突变研究结果为阴性。

干预措施及结果

尝试了以下治疗方法:i)皮下注射重组人 PTH(rhPTH)1 - 34 联合口服骨化三醇、钙和镁,部分有效,但注射 20 微克 rhPTH 后 4 小时症状复发;即使每天注射 4 - 6 次特立帕肽,也未实现血钙稳定;ii)进行了两次异体甲状旁腺移植试验,但 3 个月后检测到排斥反应;iii)静脉注射镁可降低 rhPTH 需求量,但肌肉注射无法耐受;iv)多次皮下输注特立帕肽,以相对较低的 rhPTH 剂量(每日 25 - 35 微克)使血清钙、磷、镁、尿钙和尿镁完全恢复正常,且持续了一年多。

结论

术后甲状旁腺功能减退症发生时,维生素 D 无反应会导致低钙血症无法控制;在对常规剂量或更高剂量维生素 D 及皮下注射 rhPTH 无反应的情况下,使用特立帕肽多次皮下输注器治疗是一种有效且安全的替代方法。

相似文献

1
Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.采用特立帕肽多脉冲皮下输注成功治疗维生素D无反应性甲状旁腺功能减退症。
Eur J Endocrinol. 2008 Nov;159(5):653-7. doi: 10.1530/EJE-08-0269. Epub 2008 Aug 14.
2
Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide.甲状旁腺激素脉冲皮下输注治疗无反应性甲状旁腺功能减退症的长期疗效和安全性。
Horm Metab Res. 2012 Sep;44(9):708-10. doi: 10.1055/s-0032-1308971. Epub 2012 Apr 2.
3
Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.皮下注射重组甲状旁腺激素(1-84)在甲状旁腺功能减退患者中的药代动力学和药效学:一项开放标签、单剂量、I期研究。
Clin Ther. 2014 May;36(5):722-36. doi: 10.1016/j.clinthera.2014.04.001. Epub 2014 May 5.
4
Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series.重组人特立帕肽治疗术后甲状旁腺功能减退患者严重危及生命的低钙血症——病例系列
Endokrynol Pol. 2016;67(4):403-12. doi: 10.5603/EP.a2016.0051. Epub 2016 Jul 8.
5
Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.甲状旁腺激素用于甲状旁腺功能减退症患者低钙血症的药物安全性评估。
Expert Opin Drug Saf. 2017 May;16(5):617-625. doi: 10.1080/14740338.2017.1311322. Epub 2017 Apr 3.
6
[Reduction in requirements of oral calcium and 1-25 dihydroxy vitamin D in patients with post-surgical hypoparathyroidism treated with teriparatide (PTH1-34)].特立帕肽(PTH1-34)治疗术后甲状旁腺功能减退患者时口服钙及1,25-二羟维生素D需求的降低
Gac Med Mex. 2016 May-Jun;152(3):322-8.
7
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.重组人甲状旁腺激素rhPTH(1-84)对甲状旁腺功能减退症患者磷稳态及维生素D代谢的影响:REPLACE 3期研究
Endocrine. 2017 Jan;55(1):273-282. doi: 10.1007/s12020-016-1141-0. Epub 2016 Oct 12.
8
Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.重组人生长激素(1-84)在甲状旁腺功能减退症中的疗效和安全性(REPLACE):一项双盲、安慰剂对照、随机、3 期研究。
Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83. doi: 10.1016/S2213-8587(13)70106-2. Epub 2013 Oct 7.
9
Sporadic hypoparathyroidism treated with teriparatide: a case report and literature review.用特立帕肽治疗散发性甲状旁腺功能减退症:一例报告及文献综述
Exp Clin Endocrinol Diabetes. 2007 Jan;115(1):50-4. doi: 10.1055/s-2007-967088.
10
Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism.特立帕肽(重组人甲状旁腺激素)治疗综合征性甲状旁腺功能减退症患儿
J Pediatr Endocrinol Metab. 2014 Jan;27(1-2):53-9. doi: 10.1515/jpem-2013-0159.

引用本文的文献

1
Parathyroid Allotransplantation: A Systematic Review.甲状旁腺同种异体移植:系统评价。
Med Sci (Basel). 2022 Mar 15;10(1):19. doi: 10.3390/medsci10010019.
2
Mini-review: pump therapy in endocrinology & metabolism beyond diabetes.综述:糖尿病以外内分泌与代谢领域的泵治疗
Endocrine. 2022 May;76(2):245-252. doi: 10.1007/s12020-022-03007-w. Epub 2022 Feb 15.
3
Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism.经奥曲肽泵给予特立帕肽治疗难治性甲状旁腺功能减退症 2 例初步经验。
Endocrine. 2022 Apr;76(1):179-188. doi: 10.1007/s12020-021-02978-6. Epub 2022 Jan 4.
4
Off-Label Use of Teriparatide in Spine.特立帕肽在脊柱方面的超说明书用药
Cureus. 2021 Jul 20;13(7):e16522. doi: 10.7759/cureus.16522. eCollection 2021 Jul.
5
Post-Operative Permanent Hypoparathyroidism and Preoperative Vitamin D Prophylaxis.术后永久性甲状旁腺功能减退与术前维生素D预防
J Clin Med. 2021 Jan 24;10(3):442. doi: 10.3390/jcm10030442.
6
Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism.慢性甲状旁腺功能减退症的连续 rhPTH(1-34)治疗
Endocrinol Diabetes Metab Case Rep. 2020 May 29;2020. doi: 10.1530/EDM-20-0009.
7
Alternative treatment of resistant hypoparathyroidism by intermittent infusion of teriparatide using an insulin pump: A case report.使用胰岛素泵间歇性输注特立帕肽治疗难治性甲状旁腺功能减退症:一例报告
Turk J Phys Med Rehabil. 2019 May 2;65(2):198-201. doi: 10.5606/tftrd.2019.2718. eCollection 2019 Jun.
8
Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus.成人甲状旁腺功能减退症的护理标准:加拿大与国际共识
Eur J Endocrinol. 2019 Mar;180(3):P1-P22. doi: 10.1530/EJE-18-0609.
9
Management of Hypoparathyroidism: Present and Future.甲状旁腺功能减退症的管理:现状与未来
J Clin Endocrinol Metab. 2016 Jun;101(6):2313-24. doi: 10.1210/jc.2015-3910. Epub 2016 Mar 3.
10
Impact of recombinant PTH on management of hypoparathyroidism: a systematic review.重组甲状旁腺激素对甲状旁腺功能减退症管理的影响:一项系统评价
Eur Arch Otorhinolaryngol. 2016 Apr;273(4):827-35. doi: 10.1007/s00405-014-3484-6. Epub 2015 Jan 8.